Patients for whom metformin is contraindicated, such as those with renal disease or renal dysfunction because of the risk of lactic acidosis, or for whom metformin should not be initiated, such as patients ≥ 80 years of age unless adequate renal function has been demonstrated, are candidates for treatment with DPP-4 inhibitors 29. The gene discussed is DPP4; the disease is kidney disorder.